Collaborations and Distribution Deals Bodes Well for Market Expansion- Report on EPIRUS Biopharmaceuticals

Jul 20, 2015, 09:15 ET from www.aciassociation.com

NEW YORK, July 20, 2015 /PRNewswire/ --

ACI Association has initiated research coverage on EPIRUS Biopharmaceuticals, Inc. (NASDAQ: EPRS). Select highlights from the internally released reports are being made available to the general public (included below), with access to the entirety of the research available to new members.

Today, membership is open to readers on a complementary basis at the following URL: http://www.aciassociation.com/?c=EPRS

Highlights from our EPRS Report include:

  • Collaboration for Biosimilars Pipeline -- On July 14, 2015, EPIRUS Biopharmaceuticals Inc. (EPIRUS) and Polpharma Group- a leading generics company based in Poland, announced that they have entered into a multi-product, multi-region profit-sharing collaboration for the commercialization of EPIRUS biosimilars pipeline in EU, Middle East, Turkey, Russia and CIS territories. As per the release, the collaboration relates for select EPIRUS biosimilars, including BOW015 (infliximab, reference biologic Remicade®), BOW050 (adalimumab, reference biologic Humira®) and BOW070 (tocilizumab, reference biologic Actemra®), which represents $6 billion in innovator sales in the specified territories.
  • Terms of Collaboration -- Under the collaboration, EPIRUS would lead the global product development and clinical programs and will also be responsible for process development, scale-up and manufacturing, with Polpharma overseeing commercialization across the territories. Furthermore, both parties will jointly fund clinical development and collaborate on regulatory filings in the specified territories. Under the agreement, Polpharma will bear 51% of Clinical development costs and eventual operating profit while contribution from EPIRUS will amount to 49%. The Company noted that Polpharma will contribute approximately $30 million towards clinical development costs, as well as cover product launch costs across all three programs. EPIRUS added that it retains the commercial rights of aforesaid EPIRUS biosimilars pipeline to Switzerland and Norway along with select EU countries including Austria, Belgium, Denmark, Finland, Luxembourg, the Netherlands and Sweden.
  • Other Developments related to Infliximab Biosimilar, BOW015 -- Earlier on May 14, 2015 EPIRUS informed that the Company, and mAbxience - a biopharmaceutical company specialized in research, development and manufacturing of biosimilars, have entered into a development and future distribution deal for EPIRUS' lead program, BOW015, for Latin American markets, including Argentina, Chile, Ecuador, Paraguay, Uruguay and Venezuela. EPIRUS highlighted that under the deal mAbxience will be responsible for regulatory submissions, using BOW015's existing data package, and eventual commercialization in these select Latin American markets. mAbxience is a wholly-owned subsidiary of CHEMO Group which generates over $1 billion in annual revenues with 5,000 professionals across 40 countries.

To find out how this influences our rating on EPIRUS Biopharmaceuticals, Inc.read the full report in its entirety here: http://www.aciassociation.com/?c=EPRS

About ACI Association: 

Active Charter Investors Association ("ACI Association") produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. ACI Association has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

ACI Association has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:  

The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer"). Rohit Tuli, a CFA® charter holder (the "CFA®"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on sound investment judgment and publicly available information which is believed to be reliable. The Reviewer and the CFA® have not performed any independent investigations or forensic audits to validate the information herein. Unless otherwise noted, any content outside of this document has no association with the Author, the Reviewer, or the CFA® (collectively referred to as the "Production Team") in any way. The Production Team is compensated on a fixed monthly basis and do not hold any positions of interest in any of the securities mentioned herein.

NO WARRANTY 

ACI Association, the Author, the Reviewer and the CFA® (collectively referred to as the "Publishers") are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by the Publishers whatsoever for any direct, indirect or consequential loss arising from the use of this document. The Publishers expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, the Publishers do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING 

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither ACI Association nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://www.aciassociation.com/.

RESTRICTIONS 

ACI Association is not available to residents of Belarus, Cuba, Canada, Iran, North Korea, Sudan, Syria or Somalia. Do not send email to robottrap (at) aciassociation.com.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE www.aciassociation.com